TY - JOUR T1 - High-sensitivity troponin predicts coronary disease outcomes in type 2 diabetes but yields no benefit in selecting patients for revascularisation JF - Evidence Based Medicine JO - Evid Based Med SP - 100 LP - 100 DO - 10.1136/ebmed-2016-110405 VL - 21 IS - 3 AU - Juhani Junttila Y1 - 2016/06/01 UR - http://ebm.bmj.com/content/21/3/100.abstract N2 - Commentary on: Everett BM, Brooks MM, Vlachos HE, et al., BARI 2D Study Group. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015;373:610–20.OpenUrlCrossRefPubMedHigh-sensitivity troponin (hs-TnT) assays have been developed for early recognition of patients with acute coronary syndrome (ACS). Additionally, hs-TnT has been shown to be a feasible tool for assessing risk among patients with heart failure. Even though efforts have been made to improve prognosis among patients with coronary artery disease (CAD) with high-risk features, most adverse events occur in patients without these features. Therefore, novel risk markers for ‘intermediate risk’ participants are needed. Recent evidence presents hs-TnT as a promising marker for adverse events among patients with stable CAD.1 ,2 The pathophysiological background for these findings and therapeutic … ER -